Thyroid Panel Reference Tool

What Is a Thyroid Panel?

A standard thyroid panel measures three hormones that together describe how the thyroid axis is functioning: TSH (thyroid-stimulating hormone) released by the pituitary gland, and the two main thyroid hormones it controls — Free T4 (thyroxine) and Free T3 (triiodothyronine), measured in their unbound, biologically active forms. Many laboratories report total T4 and total T3 as well, but the free fractions are more clinically informative because they are not affected by changes in binding-protein concentration. Reverse T3 (rT3) is occasionally requested but the American Thyroid Association does not consider it useful for routine clinical practice; rT3 rises in non-thyroidal illness and starvation but does not change diagnosis or treatment of common thyroid disorders.

The thyroid releases mostly T4 (about 80 percent), which is then converted in peripheral tissues to the more active T3 by deiodinase enzymes. T3 binds to nuclear receptors and regulates the transcription of genes involved in metabolic rate, body temperature, heart rate, and cognitive function. TSH from the pituitary acts as the master controller: it rises when the thyroid produces too little hormone and falls when the thyroid produces too much.

Why TSH Is the First-Line Test

The pituitary–thyroid feedback loop is logarithmic: small changes in circulating Free T4 and Free T3 produce relatively large, easily detectable changes in TSH. This makes TSH the single most sensitive blood marker of primary thyroid dysfunction. The American Thyroid Association and other major endocrine societies recommend TSH as the initial screening test in adults with no prior thyroid disease, with Free T4 (and sometimes Free T3) added when TSH is abnormal or when central (pituitary or hypothalamic) thyroid disease is suspected. In primary hypothyroidism TSH typically rises before Free T4 falls; in primary hyperthyroidism TSH suppresses before Free T4 and Free T3 rise to clinical levels.

Reference Ranges by Population

Sources: Garber JR et al. (American Thyroid Association/AACE 2012 hypothyroidism guideline), Bahn RS et al. (ATA/AACE 2011 hyperthyroidism guideline), ATA 2014 hypothyroidism update, Alexander EK et al. (ATA 2017 pregnancy and postpartum guideline). Free T4 and Free T3 reference ranges are highly assay-dependent — always defer to your laboratory's printed range.

Optimal Range vs Reference Range

One of the most contested questions in modern thyroidology is whether the upper end of the normal TSH range should be lower than the typical 4.0 to 5.0 mIU/L printed by most laboratories. The National Academy of Clinical Biochemistry (NACB) argued for a narrower upper limit closer to 2.5 mIU/L, on the basis that excluding individuals with subclinical autoimmune thyroid disease (positive TPO antibodies, family history) tightens the reference distribution substantially. Some integrative and functional medicine practitioners refer to a TSH between 0.5 and 2.5 mIU/L as the "optimal" range and consider values above this potentially symptomatic.

The American Thyroid Association 2014 position is more conservative: the upper limit of approximately 4.0 mIU/L remains appropriate for non-pregnant adults, and lowering the cutoff would reclassify many healthy individuals as having thyroid disease without clear evidence of clinical benefit. Research suggests the truth is somewhere in between — a TSH of 3.5 mIU/L is technically within range but, in a symptomatic patient with positive TPO antibodies, reasonably warrants monitoring or even a trial of therapy. Single thresholds are practical guides, not biological truths; trend over time, antibody status, and symptoms matter more than any single reading.

Subclinical Hypothyroidism (Educational Background)

Research suggests that subclinical hypothyroidism is defined biochemically as a raised TSH with a normal Free T4. Population prevalence may be on the order of 4 to 10 percent of adults, rising with age and being more common in women. Most people with mild subclinical hypothyroidism (TSH 4 to 10 mIU/L) are reportedly asymptomatic, and many do not progress to overt disease. The 2014 ATA hypothyroidism guideline and the Cooper and Biondi 2012 New England Journal of Medicine review describe a similar framework that consensus thresholds typically suggest: levothyroxine treatment is most clearly considered when TSH exceeds 10 mIU/L, when symptoms are present alongside positive TPO antibodies, during pregnancy or pre-conception, and in younger people with cardiovascular risk factors. In older adults with mildly elevated TSH and no symptoms, the threshold clinicians use is generally higher because over-replacement carries its own risks (atrial fibrillation, bone loss).

Subclinical Hyperthyroidism (Educational Background)

Subclinical hyperthyroidism is the mirror image: low or suppressed TSH with normal Free T4 and Free T3. It is less common than subclinical hypothyroidism but may be more clinically consequential. Cappola and colleagues reported in 2015 that endogenous subclinical hyperthyroidism may be associated with increased risks of atrial fibrillation, fracture, and cardiovascular events, particularly when TSH is below 0.1 mIU/L. Research suggests treatment is commonly considered when TSH is persistently below 0.1 mIU/L, or in older adults and those with osteoporosis or cardiovascular disease — though decisions are individualised and depend on the underlying cause (Graves' disease, toxic nodule, or exogenous thyroid hormone).

Hashimoto's vs Graves' Disease

The two most common autoimmune thyroid disorders are Hashimoto's thyroiditis (the leading cause of hypothyroidism in iodine-replete countries) and Graves' disease (the leading cause of hyperthyroidism). Both are diagnosed by combining biochemistry with antibody testing:

• Anti-TPO antibodies (TPOAb) — positive in approximately 90 percent of Hashimoto's and 70 percent of Graves' cases. The most useful single autoimmune thyroid antibody test.
• Anti-thyroglobulin antibodies (TgAb) — positive in roughly 50 to 70 percent of Hashimoto's cases. Used alongside TPOAb when TPO is negative but autoimmunity is still suspected.
• TSH-receptor antibodies (TRAb), including thyroid-stimulating immunoglobulins (TSI) — the diagnostic test for Graves' disease and a powerful prognostic marker.

Research suggests that antibody status influences how a borderline TSH is interpreted clinically. A person with TSH 4.5 mIU/L and positive TPO may be more likely to progress to overt hypothyroidism than someone with the same TSH and negative antibodies, and is commonly monitored more closely. Any interpretation of antibody status alongside a thyroid panel is the role of a qualified clinician, not this tool.

Pregnancy: Why the Ranges Shift

Pregnancy substantially alters thyroid physiology. Human chorionic gonadotropin (hCG) has weak thyroid-stimulating activity and peaks in the first trimester, which may suppress TSH; thyroxine-binding globulin rises sharply due to oestrogen, increasing total T4 and T3 (free fractions remain closer to baseline); and the maternal thyroid produces roughly 50 percent more hormone to meet fetal demand. The ATA 2017 pregnancy guideline recommends using local trimester-specific reference ranges where possible. When unavailable, suggested defaults are approximately 0.1 to 2.5 mIU/L in the first trimester and 0.2 to 3.0 mIU/L in the second and third trimesters. Research suggests that treating overt hypothyroidism in pregnancy is important for fetal neurocognitive development, and consensus guidance generally suggests that subclinical hypothyroidism is also commonly treated when TPO antibodies are positive. Pregnancy-related thyroid evaluation is always managed by a qualified clinician.

Medications and Conditions That May Shift TSH

• Biotin supplements — research suggests that high-dose biotin (5,000 to 10,000 micrograms daily) can interfere with the streptavidin-biotin chemistry used in many thyroid immunoassays. The pattern can resemble hyperthyroidism (low TSH, high Free T4/Free T3, sometimes false-positive TRAb). The FDA issued a safety communication on this in 2017. Many laboratories suggest holding biotin for at least 48 hours, ideally a week, before testing.
• Glucocorticoids and dopamine — may suppress TSH at high doses, particularly in inpatient and ICU settings.
• Severe non-thyroidal illness (NTI), or "euthyroid sick syndrome" — may produce low T3, occasionally low T4, and variable TSH. Thyroid testing is generally avoided in acutely unwell hospital patients unless thyroid disease is strongly suspected.
• Levothyroxine timing — consensus guidance typically suggests taking levothyroxine on an empty stomach, ideally 30 to 60 minutes before food, calcium, iron, or coffee. Recent dose changes may take 6 to 8 weeks to fully reflect in TSH; testing too soon after a dose change can be misleading.
• Amiodarone, lithium, interferon-alpha, tyrosine kinase inhibitors — may induce thyroid dysfunction. People on these drugs are commonly monitored on a clinician-led schedule.
• Time of day — TSH has a diurnal rhythm, peaking overnight and falling in the morning and afternoon. More consistent results commonly come from sampling at a similar time of day across visits.

When Clinical Review Is Commonly Suggested

Research suggests that any frankly abnormal TSH, persistent borderline TSH on repeat testing, or thyroid panel with conflicting findings benefits from review by a clinician. Consensus guidance generally suggests prompt review for severely suppressed TSH below 0.1 mIU/L (especially when palpitations, atrial fibrillation, or weight loss are present), TSH above 10 mIU/L, an unusual pattern of normal TSH with abnormal Free T4 (which may be associated with central thyroid disease, recent treatment change, or assay interference), thyroid concerns during pregnancy or pre-conception, and any thyroid result accompanied by a neck mass, voice change, or rapid heart rhythm. Specialist endocrinology input is commonly involved for pregnancy, refractory disease, suspected autoimmune thyroid conditions, or thyroid nodules.